A pharmacovigilance study of gender differences in rhabdomyolysis risk among donepezil users with alzheimer`s disease

Abstract

Alzheimer’s disease is the most common disease for older patients marked by symptoms of dementia. This study was conducted for the pharmacovigilance investigation of donepezil related to adverse event rhabdomyolysis among gender variation by collecting data from FDA Adverse Event Reporting System database (January 2016 to June 2023). RStudio was used to calculate the reporting odds ratio (ROR). In case of male, the ROR along with 95% CI value was 10.97, when considering the whole database as a comparator and 4.93, when considering the AChEIs class as a comparator. On the other hand, the ROR (95% CI) was found to be 5.71 by considering the whole database as a comparator and 1.82 by considering AChEIs class as a comparator in case of female patients. After calculating and interpreting ROR, male patients are more associated with rhabdomyolysis. More research can be conducted in the future on those findings.